Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 2, 2016

View Archived Issues

Vimpat launched in Japan as adjunctive therapy for partial onset seizures

AstraZeneca and Aspen complete anesthetics commercialization agreement

FDA grants fast track designation to APL-130277 to treat off episodes in Parkinson's disease

Pfizer presents data on new JAK1/TYK2 inhibitor

Genetech discloses KDM5 inhibitors for the potential treatment of cancer

Genentech describes new CREB-binding protein inhibitors

Shanghai De Novo Pharmatech patents IDO1 and/or TOD2 inhibitors

Genentech and Roche disclose TRPA1 antagonists

Enanta Pharmaceuticals describes FXR agonists

Merck & Co. develops retinoid RORgammaT antagonists

Incyte announces PI3Kgamma inhibitors

Johns Hopkins and Salk co-lead an initiative to advance bipolar disorder and schizophrenia research

PCI Biotech and BioNTech establish preclinical research collaboration

FDA approves Blincyto for pediatric patients with Ph-negative B-cell precursor ALL

FDA awards fast track designation to aducanumab in Alzheimer's disease

Omecamtiv mecarbil enters phase III clinical development

Chugai transfers the manufacturing and marketing rights for Vesanoid

Myriad Genetics completes Assurex Health acquisition

AdAlta receives grant for the development of AD-114 in IPF

FDA accepts Array's NDA for binimetinib

Lytix's LYX-315 studied at Massachusetts General Hospital and Harvard Medical School

BARDA selects Takeda Vaccines for the development of Zika vaccine

European Commission approves expanded use of Xultophy

Alnylam's ALN-AS1 receives FDA orphan drug designation

TLR4 expression predicts response to immunosuppressive therapy in patients with myocarditis

University of Dundee, GlaxoSmithKline develop novel compound for leishmaniasis

New microRNAs linked to 10-year risk of fatal myocardial infarction

Genmab wins sBLA for ofatumumab in CLL

SAGE-217 shows promise for seizure disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...